To assess the efficacy and safety of oral decernotinib ( VX-@ ; Vertex Pharmaceuticals ) monotherapy in a @-week , randomized , double-blind , placebo-controlled , dose-ranging study of patients with rheumatoid arthritis ( RA ) .